Leighl NB, et al. - In this multicohort, open-label, phase 1 study, investigators examined 550 individuals to estimate the 3-year safety and effectiveness outcomes of pembrolizumab in subjects with advanced non-small-cell lung cancer. A correlation between a programmed death ligand 1 (PD-L1) tumor proportion score ≥50% with longer median overall survival vs a tumor proportion score 1-49% was noted. In 12% of cases, they noted grade 3–5 treatment-related adverse events; 6% of subjects discontinued due to a treatment-related adverse event. Pneumonitis and fatigue were the most frequently observed grade 3–4 treatment-related adverse events. For both treatment-naive and earlier treated advanced non-small-cell lung cancer expressing PD-L1, durable response and long-term outcomes on overall survival were provided by pembrolizumab.